Donepezil is a centrally-acting reversible acetylcholinesterase inhibitor indicated for the treatment of mild, moderate, and severe Alzheimer's disease. It is the most widely prescribed medication for Alzheimer's dementia and provides modest improvements in cognition, behavior, and daily function, though it does not alter disease progression.
Known hypersensitivity to donepezil or piperidine derivatives1,2
Sick sinus syndrome or cardiac conduction disorders without a pacemaker3
The bottom line
Evidence rating moderate. Most-documented uses: modest improvement in cognitive function (adas-cog scores), may stabilize or slow decline in activities of daily living, once-daily dosing with simple titration. 10 sources indexed (2008–2025), with 3 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Reversibly inhibits acetylcholinesterase (AChE), the enzyme responsible for breaking down acetylcholine in the synaptic cleft. By preventing acetylcholine degradation, it increases cholinergic neurotransmission in the cerebral cortex and hippocampus, partially compensating for the loss of cholinergic neurons characteristic of Alzheimer's disease. Highly selective for AChE over butyrylcholinesterase.
Class
Cholinesterase Inhibitor / Alzheimer's
Dosing
Dosing & protocol.
Common range
5 mg once daily at bedtime for 4-6 weeks, then may increase to 10 mg once daily; 23 mg once daily for moderate-to-severe AD (as prescribed by your physician)
Recommended form
Oral tablet or orally disintegrating tablet; 23 mg sustained-release tablet for advanced disease
Well absorbed (~100% bioavailability); food does not affect absorption. Usually taken at bedtime to minimize GI side effects. Long half-life supports once-daily dosing.
Safety
Full safety detail.
Side effects
Nausea and vomiting
Diarrhea
Insomnia and vivid dreams
Muscle cramps
Fatigue
Bradycardia
Decreased appetite and weight loss
Contraindications
Known hypersensitivity to donepezil or piperidine derivatives1,2
Sick sinus syndrome or cardiac conduction disorders without a pacemaker3
Active GI bleeding or peptic ulcer disease
Severe COPD or asthma (cholinergic bronchoconstriction risk)10
Both donepezil and Alpha-GPC increase cholinergic activity. Donepezil inhibits acetylcholinesterase; Alpha-GPC provides choline for acetylcholine synthesis. Combined use may cause cholinergic excess (nausea, diarrhea, bradycardia).
Recommendation: If combining, start Alpha-GPC at low doses (300mg) and monitor for cholinergic side effects (nausea, diarrhea, muscle cramps, bradycardia).
Both donepezil and ginkgo biloba have cholinergic and cognitive effects. Some studies have explored the combination, but additive cholinergic side effects and ginkgo's antiplatelet activity warrant caution.
Recommendation: May be used under medical supervision for cognitive support. Monitor for GI side effects and bleeding signs.
Citicoline has been studied as an adjunct to acetylcholinesterase inhibitors such as donepezil in Alzheimer's disease. Observational data and a systematic review suggest possible additional benefit for cognition and behavioral symptoms, with generally mild adverse effects. This should be treated as an adjunctive dementia-care option, not a replacement for donepezil or diagnostic follow-up.
Recommendation: Consider citicoline only as an add-on after discussing it with the clinician managing dementia therapy. Monitor for headache, excitability, stomach upset, sleep change, or worsening confusion after starting it. Do not change donepezil dosing on your own.
Wu Y, Zhan Y, Zhu W et al.. Effectiveness of acupuncture combined with donepezil for Alzheimer's disease: A systematic review and meta-analysis. Medicine. 2025
Fornalik M, Moska S, Gimła M et al.. Donepezil for cancer-related cognitive impairment: systematic review and meta-analysis. Clinical and experimental medicine. 2025
Nham T, Garcia MC, Tsang KJ et al.. Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta-analysis. Journal of the American Geriatrics Society. 2024
Liu L, Zhang CS, Zhang AL et al.. Oral Chinese herbal medicine combined with donepezil for mild cognitive impairment: A systematic review and meta-analysis. Journal of the American Geriatrics Society. 2024
Zhang X, Lian S, Zhang Y et al.. Efficacy and safety of donepezil for mild cognitive impairment: A systematic review and meta-analysis. Clinical neurology and neurosurgery. 2022
Yang Q, Liu J, Huang KL et al.. A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia. Medicine. 2022
Hansen RA, Gartlehner G, Webb AP et al.. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clinical interventions in aging. 2008
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Donepezil in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.